Company intelligence / Profile preview
PainReform
Tel Aviv, Israelpainreform.com ↗
- Ownership
- Public · PRFX
- Development stage
- Phase 3
01
Overview
The lead candidate, PRF‑110, demonstrated a solid safety profile with no serious adverse events in early Phase III trials for bunionectomy patients. Plasma concentrations were well below FDA safety thresholds. However, the company encountered a temporary setback due to a data gap in the final phase of its Phase III trial and has initiated further R&D to address this before resuming clinical work.
- Therapeutic areas
- OtherGastroenterologyNeurology
- Modalities
- Small moleculeOil-based drug delivery system
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on PainReform.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PainReform.